ACCENDRA HEALTH 2026: Revenue $613.23M, EPS ($1.16) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.Accendra Health reported Q2 2026 net revenue of $613.23M, a 10.1% YoY decline due to the loss of major payor contracts removing ~$81M in revenue. Net loss narrowed significantly to ($89.07M) from ($869.06M), with diluted EPS improving to ($1.16) from ($11.3). Excluding contract impacts, Diabetes, Ostomy, and Urology segments showed growth. The company also sold its Products & Healthcare Services business and reduced SG&A through operational efficiencies.
ACCENDRA HEALTH reported second-quarter 2026 results with net revenue of $613.23M and a net loss of ($89.07M), or diluted loss per share of ($1.16), versus prior-year quarter revenue of $681.92M and a net loss of ($869.06M) (diluted loss per share ($11.3)).
Financial Highlights
| Metric | Current quarter | Prior year quarter | YoY change |
| Revenue¹ | $613.23M | $681.92M | (10.1%) |
| Net income² | ($89.07M) | ($869.06M) | 89.8% |
| Diluted EPS³ | ($1.16) | ($11.3) | 89.7% |
¹ Reported as “Net revenue”. ² Reported as “Net loss”. ³ Reported as “Diluted loss per common share”.
Business Highlights
- Revenue trends: Net revenue declined roughly 10% in Q2 and about 8.5% year-to-date, driven largely by the loss of a commercial payor contract that reduced capitation and related sales.
- Channel shift & contract loss: Termination of major payor contracts completed in H1 2026 removed approximately $81M in Q2 and $123M year-to-date revenue, notably impacting sleep and home respiratory therapy.
- Product mix momentum: Excluding payor termination impacts, Diabetes, Ostomy and Urology showed growth in Q2 of about $7.8M, $3.8M and $2.6M, respectively.
- Operational actions: Completed sale of the Products & Healthcare Services business (retaining a 5% equity stake) and executed balance-sheet optimization to focus core operations and transition services.
- Operational efficiency: SG&A was reduced versus the prior year through personnel and other savings; equipment sales in H1 generated meaningful proceeds tied to contract transitions.
Original SEC Filing: ACCENDRA HEALTH INC/VA/ [ ACH ] - 10-Q - Aug. 10, 2026